We are live on ! Find out more
CG

Carlyle Group Portfolio holdings

AUM $10.6B
1-Year Est. Return 11.25%
This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+11.25%
3 Year Est. Return
-0.47%
5 Year Est. Return
-4.92%
10 Year Est. Return
+7.54%
AUM
$2.31B
AUM Growth
-$502M
Cap. Flow
-$9.67M
Cap. Flow %
-0.42%
Top 10 Hldgs %
95.16%
Holding
27
New
1
Increased
1
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
SPWR icon
SunPower Inc
SPWR
+$10M
2
SLNO
Soleno Therapeutics
SLNO
+$6.61M

Top Sells

Rank Stock Value
1
VERA icon
Vera Therapeutics
VERA
+$16.8M
2
GTM
ZoomInfo Technologies
GTM
+$5.83M
3
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$2.3M
4
GETY icon
Getty Images
GETY
+$1.28M
5
SYRE icon
Spyre Therapeutics
SYRE
+$108K

Sector Composition

Rank Sector Weight
1 Healthcare 49.41%
2 Technology 41.11%
3 Consumer Staples 4.78%
4 Communication Services 2.74%
5 Real Estate 1.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
1
QuidelOrtho
QDEL
$1.19B
$910M 39.47%
12,460,183
– –
GTM
2
ZoomInfo Technologies
GTM
$905M
$597M 25.88%
36,377,293
-285,176
-0.8% -$5.83M
MKSI icon
3
MKS Inc
MKSI
$21.9B
$301M 13.07%
3,482,732
– –
VTRU
4
DELISTED
Vitru Limited Common Shares
VTRU
$110M 4.77%
6,246,471
– –
SLNO
5
DELISTED
Soleno Therapeutics
SLNO
$67.4M 2.92%
2,293,562
+1,092,056
+91% +$6.61M
GETY icon
6
Getty Images
GETY
$216M
$63.1M 2.74%
9,722,246
-254,054
-3% -$1.28M
GDS icon
7
GDS Holdings
GDS
$6.24B
$44.6M 1.93%
4,072,624
– –
VRNA
8
DELISTED
Verona Pharma
VRNA
$40M 1.74%
2,457,500
– –
PHAT icon
9
Phathom Pharmaceuticals
PHAT
$873M
$36.2M 1.57%
3,496,808
– –
HLVX
10
DELISTED
HilleVax
HLVX
$24.7M 1.07%
1,838,486
– –
OKUR
11
OnKure Therapeutics
OKUR
$170M
$20.5M 0.89%
269,896
– –
VERA icon
12
Vera Therapeutics
VERA
$2.76B
$19.7M 0.85%
1,438,155
-978,682
-40% -$16.8M
SMHI icon
13
SEACOR Marine Holdings
SMHI
$214M
$18.2M 0.79%
1,314,164
– –
INVH icon
14
Invitation Homes
INVH
$17.9B
$15.1M 0.66%
477,500
– –
CUBE icon
15
CubeSmart
CUBE
$9.48B
$8.41M 0.36%
220,500
– –
SPRB
16
Spruce Biosciences
SPRB
$120M
$6.46M 0.28%
38,620
– –
JSPR icon
17
Jasper Therapeutics
JSPR
$24.8M
$6.05M 0.26%
876,189
– –
SPWR icon
18
SunPower Inc
SPWR
$102M
$5.14M 0.22%
+2,495,879
New +$10M
EM
19
DELISTED
Smart Share Global Ltd
EM
$3.63M 0.16%
4,810,209
– –
ACET icon
20
Adicet Bio
ACET
$75.9M
$2.88M 0.12%
132,212
– –
EFTR
21
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$2.87M 0.12%
192,885
– –
NCNA
22
NuCana
NCNA
$5.45M
$1.97M 0.09%
667
– –
AIU
23
DELISTED
Meta Data Limited American Depositary Shares, each representing ten (10) Class A Ordinary Shares
AIU
$326K 0.01%
62,880
– –
XCUR icon
24
Exicure
XCUR
$10.7M
$200K 0.01%
56,327
– –
MTEM
25
DELISTED
Molecular Templates, Inc.
MTEM
$84.3K ﹤0.01%
13,333
– –
1
2

Similar funds

SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $10.8B AUM 21.99% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $10.9B AUM 18.64% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

Carlyle Group's Q3 2023 Portfolio in Review

As of Q3 2023, Carlyle Group held 27 positions worth $2.31B, down 18% from $2.81B the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Carlyle Group's Q3 2023 filing shows 1 new, 1 increased, 3 reduced and 2 closed positions. Its largest new stake was SunPower Inc: 2,495,879 shares worth $5.14M. The largest sale was Vera Therapeutics, an estimated $16.8M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 45% a quarter earlier, followed by Technology and Consumer Staples.

  • Carlyle Group's largest Q3 2023 buy was SunPower Inc: 2,495,879 shares worth $5.14M.
  • Carlyle Group added most to Soleno Therapeutics in Q3 2023, an estimated $6.61M increase.
  • Carlyle Group's biggest Q3 2023 reduction was Vera Therapeutics, cutting an estimated $16.8M.
  • Carlyle Group fully exited Paratek Pharmaceuticals, Inc. in Q3 2023, selling an estimated $2.3M.
  • Carlyle Group's ten largest holdings make up 95% of its $2.31B portfolio in Q3 2023.
  • Carlyle Group opened 1 new position and closed 2 in Q3 2023.
  • Carlyle Group's portfolio value fell 18% quarter-over-quarter to $2.31B.

Based on Carlyle Group's 13F filing for Q3 2023, filed 3 Nov 2023.